Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Daniel D. Von Hoff

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4723-7681; OpenAlex author ID A5080900202, A5113928803; NIH RePORTER profile ID 1872554. Sources: ClinicalTrials.gov.

Their work

Papers
98 (first author 10, last author 18)
Trials
2 (principal investigator on 1)
Grants
2
Labs led
1
Collaborators
301
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers, 1 trial · 2013: 5 papers · 2014: 5 papers · 2015: 7 papers · 2016: 9 papers · 2017: 13 papers, 1 trial, 1 grant · 2018: 1 paper · 2019: 6 papers · 2020: 10 papers · 2021: 4 papers · 2022: 9 papers · 2023: 6 papers · 2024: 2 papers · 2025: 3 papers · 2026: 10 papers, 1 grant

Papers 50 of 98

  1. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.3840↗
  2. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancre… Co-author DOI 10.1002/cncr.70343↗
  3. Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". Co-author DOI 10.1002/cncr.70510↗
  4. Corrigendum to "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer" [… Co-author DOI 10.1016/j.redox.2026.104395↗
  5. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  6. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  7. Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. Co-author DOI 10.1038/s41698-026-01543-6↗
  8. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  9. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag232↗
  10. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.36401/jipo-25-20↗
  11. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2025.103895↗
  12. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  13. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Last author DOI 10.1093/oncolo/oyae323↗
  14. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.09.050↗
  15. Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae285↗
  16. Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2023.09.008↗
  17. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  18. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Co-author DOI 10.1038/s41467-023-42178-6↗
  19. Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer. Co-author DOI 10.1038/s41598-023-44211-6↗
  20. Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.04.017↗
  21. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  22. Effect of acoustic cluster therapy (ACT®) combined with chemotherapy in a patient-derived xenograft mouse model of pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2022.11.016↗
  23. Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Co-author DOI 10.1016/j.medj.2021.12.008↗
  24. Corrigendum to "Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma" [Semin. Cancer Biol. 75 (2021) 153-168]. Co-author DOI 10.1016/j.semcancer.2022.01.002↗
  25. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Co-author DOI 10.1038/s41417-021-00350-4↗
  26. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  27. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003945↗
  28. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  29. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Co-author DOI 10.1158/0008-5472.can-21-4222↗
  30. Increasing Stress to Induce Apoptosis in Pancreatic Cancer via the Unfolded Protein Response (UPR). Last author DOI 10.3390/ijms24010577↗
  31. Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer. Co-author DOI 10.1002/onco.13645↗
  32. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.semcancer.2020.10.001↗
  33. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  34. Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. Last author DOI 10.3389/fonc.2021.678617↗
  35. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot C… Last author DOI 10.1001/jamaoncol.2019.3394↗
  36. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.12.027↗
  37. Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Co-author DOI 10.1038/s41389-020-00285-9↗
  38. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  39. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  40. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001563↗
  41. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  42. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
  43. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
  44. Extracellular Vesicles in Diagnosis and Treatment of Pancreatic Cancer: Current State and Future Perspectives. First author DOI 10.3390/cancers12061530↗
  45. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.0684↗
  46. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.cell.2019.03.010↗
  47. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  48. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Co-author DOI 10.1016/j.ejca.2018.12.007↗
  49. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  50. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-18-0899↗

Trials 2

  1. A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Study director NCT03331562↗
  2. Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Principal investigator NCT01580397↗

Grants 2

  1. Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer U01CA214254↗
  2. Targeting Stromal Collagen in Pancreatic Cancer R01CA169281↗

Closest collaborators

The 25 strongest of 301 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haiyong Han · 34 shared papers, 1 shared grant, 2011–2026 · strength 4.32
  2. Erkut Hasan Borazanci · 24 shared papers, 2014–2026 · strength 3.71
  3. Ajay Goel · 14 shared papers, 1 shared grant, 2020–2026 · strength 3.65
  4. Gayle Jameson · 15 shared papers, 2017–2026 · strength 2.57
  5. Derek Cridebring · 12 shared papers, 2020–2026 · strength 2.03
  6. Ronald M. Evans · 10 shared papers, 2019–2026 · strength 1.42
  7. Michael T. Barrett · 11 shared papers, 2012–2026 · strength 1.14
  8. Song Cheol Kim · 6 shared papers, 2022–2026 · strength 1.12
  9. Mitsuro Kanda · 5 shared papers, 2023–2026 · strength 1.05
  10. Vincent M. Chung · 5 shared papers, 2021–2026 · strength 0.97
  11. Ramesh K. Ramanathan · 17 shared papers, 2011–2020 · strength 0.94
  12. Carlos Roberto Becerra · 6 shared papers, 2019–2026 · strength 0.85
  13. Joshua D. Rabinowitz · 4 shared papers, 2022–2026 · strength 0.83
  14. Eunsung Jun · 5 shared papers, 2022–2026 · strength 0.82
  15. Serina Ng · 6 shared papers, 2017–2023 · strength 0.78
  16. John S. Bolton · 4 shared papers, 2022–2026 · strength 0.70
  17. Joon Oh Park · 5 shared papers, 2020–2026 · strength 0.69
  18. Susan Tsai · 4 shared papers, 2022–2025 · strength 0.61
  19. David J. Propper · 3 shared papers, 2023–2026 · strength 0.56
  20. Yasuhiro Kodera · 4 shared papers, 2022–2023 · strength 0.55
  21. Ronald Lee Korn · 6 shared papers, 2011–2026 · strength 0.54
  22. Elena Gabriela Chiorean · 8 shared papers, 2013–2020 · strength 0.53
  23. Geeta G. Sharma · 3 shared papers, 2021–2022 · strength 0.52
  24. Drew Warren Rasco · 2 shared papers, 2026 · strength 0.51
  25. Diana L. Hanna · 2 shared papers, 2026 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.